NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) announced that strategic partner Emobot Health presented late-breaking pooled clinical validation data for the EMOCARE Depression Thermometer at ASCP 2026.
Across three observational studies, EMOCARE showed within-person concordance with clinician-rated MADRS of r = 0.895 (p = 0.016) and sensitivity to symptom change versus PHQ-9 of ρ = 0.834 (p < 0.001). The smartphone-based, multimodal, passive monitoring tool uses voice, facial expression, motion, and screen behavior to generate continuous depression scores and is being deployed across the Hope Therapeutics interventional psychiatry clinic network as a self-monitoring and safety-net tool.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Pooled analysis showed EMOCARE–MADRS concordance of r = 0.895 (p = 0.016)
- Sensitivity to symptom change vs PHQ-9 reached ρ = 0.834 (p < 0.001)
- Technology deployment across Hope Therapeutics network supports continuous patient monitoring
Negative
- None.
News Market Reaction – NRXP
On the day this news was published, NRXP gained 3.74%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Depression protocol partnership | Positive | +3.7% | HOPE clinics began offering Ampa ONE-D protocol for treatment-resistant depression. |
| Jun 16 | IR partnership | Positive | +1.2% | Announced strategic investor relations partnership with astr partners for biotech-focused IR support. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Partnership announcements for NRXP have historically been followed by modest positive one-day moves.
Over recent quarters, NRx has paired its interventional psychiatry build-out with strategic partnerships. A Nov 10, 2025 collaboration to deploy the Ampa ONE-D protocol in Florida clinics followed strong nonrandomized response and remission rates. A Jun 16, 2025 investor-relations partnership supported capital-markets outreach during key filing milestones. Both partnership releases saw positive next-day stock reactions, framing today’s Emobot collaboration update within a pattern of strategic ecosystem building.
Key Terms
madrs medical
phq-9 medical
gad-7 medical
digital biomarker medical
transcranial magnetic stimulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring tool for psychiatric conditions.
- Pooled analysis of three prospective observational studies demonstrated
90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016). - EMOCARE also achieved strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001) on consecutive-visit measurements.
- The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool.
SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based “Depression Thermometer” that powers the Emobot app now being deployed across the Hope Therapeutics network of interventional psychiatry clinics.
The poster, titled “Continuous Multimodal Passive Monitoring of Depressive Symptoms via Smartphone — Clinical Validation of EMOCARE,” was presented at 11:45 AM ET by Tanel Petelot, CEO and Co-founder of Emobot, and co-authored by NRx Chief Executive Officer Jonathan C. Javitt, M.D., M.P.H. The interim pooled analysis combined three prospective observational studies (EMC1, EMC2-FR, EMC2-BD) in adults with Major Depressive Disorder or Bipolar Disorder, comparing EMOCARE scores against clinician-rated MADRS and HAM-D₁₇ and self-reported PHQ-9 and GAD-7. EMOCARE achieved within-person concordance with clinician-rated MADRS of r = 0.895 (p = 0.016) and consecutive-visit sensitivity to symptom change against PHQ-9 of ρ = 0.834 (p < 0.001), with continuous scores generated across the full follow-up window and a threshold of at least seven valid days per 14-day window confirming signal robustness.
“An r = 0.895 within-person concordance with MADRS is exceptional for any digital biomarker, and unprecedented for one that asks nothing of the patient. As we build out the Hope Therapeutics network and advance NRX-100 and NRX-101 toward the patients who need them most, EMOCARE gives our clinicians something they have never had before: a continuous, real-time read on whether a treatment is working between visits. That is how we intend to deliver interventional psychiatry at scale,” said Jonathan C. Javitt, M.D., M.P.H., Founder and Chief Executive Officer of NRx Pharmaceuticals and Chief Executive Officer of Hope Therapeutics.
Approximately half of patients with treatment-resistant depression relapse within six to twelve months of an effective intervention, and clinicians often learn of those relapses well after they begin. Episodic instruments such as MADRS, HAM-D₁₇, and PHQ-9 remain the gold standard but are typically administered every two to four weeks, leaving long stretches with no visibility between visits. EMOCARE is designed to fill that gap, and its integration across the Hope Therapeutics clinic network gives NRx a continuous read on patient response alongside the interventional therapies, including TMS, IV ketamine, and hyperbaric oxygen, delivered in those clinics.
About Emobot Health
Emobot (www.emobothealth.com) is a MedTech pioneer based at the Paris Brain Institute (ICM) that has developed the world’s first passive, multimodal AI platform for automated depression assessment and relapse detection. Unlike traditional active monitoring that requires patient interaction, Emobot’s “Depression Thermometer” runs
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetic stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve remission from treatment-resistant depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
